These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23222929)

  • 1. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
    Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
    Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.
    Luna E; Agrawal P; Mehta R; Vernhes C; Viskov C; Amiral J; Warren WL; Drake DR
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):211-22. PubMed ID: 25525049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates.
    Jeske W; Litinas E; Khan H; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):294-8. PubMed ID: 22275388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
    Gerotziafas GT; Rouseau A; Mbemba E; Khartechi A; Van Dreden P; Walenga J; Fareed J; Elalamy I
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):697-704. PubMed ID: 26023170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients.
    Carroll RC; Craft RM; Whitaker GL; Snider CC; Kirby RK; Elder RF; Hennessey MD
    Thromb Res; 2007; 120(3):367-70. PubMed ID: 17150243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of low molecular weight heparin (enoxaparin) on enhanced coagulation induced by crystalloid haemodilution.
    Llewellyn RL; James MF
    Anaesthesia; 2010 Oct; 65(10):1013-6. PubMed ID: 20731638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies on biological activity of generic and branded enoxaparin in vivo and vitro.
    Tan X; Cui H
    Blood Coagul Fibrinolysis; 2015 Oct; 26(7):805-10. PubMed ID: 26270263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and pharmacological profile of generic enoxaparins used in Brazil.
    Lima MA; de Farias EH; Gray A; Sadeghi N; Gesteira TF; Cavalheiro RP; Hoppensteadt D; Fareed J; Sassaki GL; Nader HB
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):379-86. PubMed ID: 22395574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional analyses of biosimilar enoxaparins available in Brazil.
    Oliveira SN; Santos GR; Glauser BF; Capillé NV; Queiroz IN; Pereira MS; Pomin VH; Mourão PA
    Thromb Haemost; 2015 Jan; 113(1):53-65. PubMed ID: 25252953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin.
    Simons R; Mallett SV
    Anaesthesia; 2007 Nov; 62(11):1175-8. PubMed ID: 17924901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Dec; 92(6):1296-302. PubMed ID: 15583737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.